175139-41-0

Basic information

• Product Name: Pyridine, 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-
• CAS NO: 175139-41-0
• Molecular Formula: C21H29NO2
• Mol File: 175139-41-0.mol

Chemical Properties

• CAS DataBase Reference: Pyridine, 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-(175139-41-0)
• EPA Substance Registry System: Pyridine, 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-(175139-41-0)

Safety Data

• Hazardous Substances Data: 175139-41-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pyridine, 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)is utilized as a building block in the synthesis of various pharmaceutical compounds due to its unique molecular structure and reactivity. Its ability to form stable complexes with other molecules makes it a promising candidate for the development of new drugs and therapeutic agents.
Used in Agricultural Industry:
In the agricultural sector, Pyridine, 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)serves as an intermediate in the production of agrochemicals, such as pesticides and herbicides. Its chemical properties allow it to be incorporated into these products to enhance their effectiveness and selectivity in controlling pests and weeds.
Used in Chemical Reactions as a Solvent:
Pyridine, 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)is employed as a solvent in various chemical reactions due to its ability to dissolve a wide range of substances and its compatibility with different reaction conditions. Its use as a solvent can improve the efficiency and yield of these reactions, making it a valuable tool in the chemical industry.
Used in Manufacturing of Commercial Products:
Due to its versatile nature, Pyridine, 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)is an important component in the manufacturing of many commercial products. Its applications span across different industries, including pharmaceuticals, agriculture, and the chemical industry, where it contributes to the development of innovative and effective products.

Upstream product

• 175140-35-9 4-Chloro-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine 
• 584-02-1 2-pentanol 
• 4664-13-5 2,4-dihydroxy-3,6-dimethylpyridine 

Relevant articles and documents

Regioselective addition of mesitol to a 2,4-dichloropyridine

The regioseleethity of the addition of 2,4,6-trimethylphenol to 2,4-dichloro-3,6-dimethylpyridine can be controlled by the proper choice of catalyst and solvent. The use of catalytic eopper(I) salts and pyridine as solvent results in exclusive addition at

Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists

A series of 2-aryloxy-4-alkoxy-pyridines (1) was identified as novel, selective, and orally active antagonists of the corticotropin-releasing factor 1 (CRF1) receptor. Among these, compound 2 (CP-316311) is a potent and selective CRF1/sub

Corticotropin releasing factor antagonists

Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes fo

Use of CRF antagonists and renin-angiotensin system inhibitors

The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.

QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death

A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.

New uses for corticotropin releasing factor antagonists

A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula or pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.

Method of treating heart failure

This invention relates to method for treating a mammal which presents with heart failure comprising administering to a mammal a therapeutically effective amount of wherein 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine and (3,6-dime

Use of 3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridines for treating heart failure

This invention relates to treatments for a mammal which presents with heart failure comprising administering to a mammal a therapeutically effective amount of wherein 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine and (3,6-dimethyl-

CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Corticotropin-releasing factor (CRF) antagonists having formulae (I), (II) or (III) wherein the dashed lines, A, B, Y, Z, G, R. sub.3, R. sub.4, R. sub.5, R 6, R 16 and R 17 are as defined in the description, and processes for preparing them. These compou